Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
  • C07D281/02—Seven-membered rings
  • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
  • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
  • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
  • C07D303/02—Compounds containing oxirane rings
  • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/02—Oxygen as only ring hetero atoms
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
  • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
  • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction

Definitions

• the present invention relates to a process for the preparation of esters of (2R,3S)-3-(4-methoxyphenyl)-glycidic acid and particularly it relates to a process for the preparation of esters of (2R,3S)-3-(4-methoxyphenyl)-glycidic acid by enzymatic transesterification of enantiomeric mixtures.
• esters of (2R,3S)-3-(4-methoxyphenyl)-glycidic acid or (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)-propionic acid are intermediates useful for the synthesis of compound (+)-(2S,3S)-3-acetyloxy-5-[2-(dimethylamino)-ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one, a drug with coronary vasodilating activity known with the name of Diltiazem (Merck Index, XI Ed., No. 3188, page 505).
• Diltiazem Merck Index, XI Ed., No. 3188, page 505
• Diltiazem starting from esters of 3-(4-methoxyphenyl)-glycidic acid, can be carried out according to several methods in the literature.
• esters of 3-(4-methoxyphenyl)-glycidic acid in an enantiomerically pure form since such compounds are the first optically active intermediates of the synthesis.
• the process object of the present invention allows to prepare intermediates useful for the synthesis of compounds with coronary vasodilating activity.
• the enzymes useful for the transesterification reaction can be of different nature.
• lipases of animal or microbial origin or proteolytic enzymes such as for example ⁇ -chymotrypsin can be used.
• lipases of animal origin useful in the process of the present invention
• pig liver and pig pancreas lipases may be cited.
• lipases of microbial origin lipases from Candida, Mucor, Pseudomonas and Aspergillus microorganisms may be cited.
• suitable alcohols are ethanol, n-propanol, 2-propanol, n-butanol, 2-butanol, 2-methyl-2-propanol, n-pentanol, 2-pentanol, 3-pentanol, n-hexanol, n-heptanol, 2-heptanol, n-octanol, 2-octanol, cyclohexanol, cyclopentanol and 2,2-dimethyl-1,3-dioxolane-4-methanol.
• n-butanol, 2-butanol, cyclohexanol, n-octanol and 2,2-dimethyl-1,3-dioxolane-4-methanol are the preferred alcohols.
• the lipases and the proteolytic enzymes act on enantiomerically opposite substrates.
• the pancreatic enzyme, ⁇ -chymotrypsin transesterifies the ester with the desired (2R,3S)configuration, that is compound I, while the lipase transesterifies the (2S,3R)-enantiomer, that is compound ent-I.
• transesterifying agent alcohol
• R methyl or ethyl
• the enzyme can be immobilized on suitable supports according to conventional techniques.
• Suitable supports are absorbent resins, acrylate polymers, porous materials, agarose or celite.
• a further suitable solvent or mixture of solvents such as for example hexane, cyclohexane, toluene, benzene, methyl ethyl ketone, diethyl ether is used if the transesterification reaction is carried out with the lipase enzyme.
• the two esters are separated according to known techniques.
• Suitable solvents for the extraction are hexane or its mixtures with ethyl acetate, methanol and acetonitrile.
• the operative conditions of the transesterification reaction are those normally used during the enzymatic reactions.
• Such ranges are comprised between 6-11 pH units and between 0° C. and 70° C. respectively.
• the process of the present invention is carried out at a pH comprised between 6 and 8 and at a temperature comprised between 20° and 60° C.
• lipases of microbial origin and, in particular, lipases from Candida Cylindracea or ⁇ -chymotrypsin are used in the process object of the present invention.
• the process object of the present invention allows to prepare the compounds of formula I with good yields and high enantiomeric purity and to recover also the undesired enantiomer.
• the used enzyme retains its enzymatic activity and, consequently, it can be used again for several times.
• compound I can be further purified by crystallization.
• the compounds of formula I have at least about 80:20 enantiomeric ratio, their crystallization provides compounds I with a higher enantiomeric purity and this is independent from the source of the mixture.
• a 95:5 enantiomeric ratio is obtained by a simple crystallization.
• Solvents suitable for the crystallization are lower alcohol such as for example methanol, ethanol, propanol, butanol.
• esters of (2R,3S)-3-(4-methoxyphenyl)-glycidic acid having at least an 80:20 enantiomeric ratio, which consists in crystallizing such esters with a suitable solvent.
• the suspension was left at 25° C. for 26 hours under magnetic stirring.
• reaction was carried out in a similar way to that described in example 5 but by using ( ⁇ )2-butanol (0.9 ml), instead of cyclohexanol.
• a chromatographic column (internal diameter 2 cm) was filled with a mixture constituted by lipase from Candida Cylindracea (AMANO Pharm. Co. Ltd.) (10 g) and celite (12.6 g).
• the column was eluted with a solution of ( ⁇ )2-butanol in cyclohexane (200 ml) (30:200 volumetric ratio) under slight pressure of nitrogen.
• the eluate was re-charged for 7 times on the column.
• pH 7.4 phosphate buffer (410 ml) constituted by a 0.1M sodium hydroxide solution and by a 0.2M monopotassium phosphate solution was added.
• the mixture was left at 25° C. for 4.5 hours under magnetic stirring.
• the phases were separated and the aqueous phase was extracted with methylene chloride (2 ⁇ 150 ml).
• the collected organic extracts were evaporated at reduced pressure.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Microbiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Analytical Chemistry (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Epoxy Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (1)

Applications Claiming Priority (5)

Related Parent Applications (1)

Publications (1)

Family

ID=11165937

Family Applications (2)

Family Applications After (1)

Country Status (13)

Cited By (3)

Families Citing this family (8)

Citations (10)

• 1990
  • 1990-05-17 IT IT02034890A patent/IT1249777B/it active IP Right Grant
• 1991
  • 1991-05-03 CH CH1329/91A patent/CH682670A5/it not_active IP Right Cessation
  • 1991-05-14 CA CA002042535A patent/CA2042535C/en not_active Expired - Lifetime
  • 1991-05-14 DE DE4115697A patent/DE4115697C2/de not_active Expired - Fee Related
  • 1991-05-14 AT AT0099591A patent/AT400446B/de not_active IP Right Cessation
  • 1991-05-15 FR FR9105866A patent/FR2662178B1/fr not_active Expired - Fee Related
  • 1991-05-16 SE SE9101482A patent/SE509297C2/sv not_active IP Right Cessation
  • 1991-05-16 NL NL9100854A patent/NL194616C/nl not_active IP Right Cessation
  • 1991-05-16 BE BE9100458A patent/BE1005406A0/fr not_active IP Right Cessation
  • 1991-05-16 JP JP3210541A patent/JP3060187B2/ja not_active Expired - Lifetime
  • 1991-05-16 GB GB9110610A patent/GB2246351B/en not_active Expired - Fee Related
  • 1991-05-16 ES ES9101193A patent/ES2033203B1/es not_active Expired - Fee Related
  • 1991-09-30 GB GB9120710A patent/GB2247020B/en not_active Expired - Fee Related
• 1995
  • 1995-03-14 US US08/404,284 patent/US5571704A/en not_active Expired - Lifetime
  • 1995-06-07 US US08/487,584 patent/US6346632B1/en not_active Expired - Fee Related
• 1999
  • 1999-11-05 JP JP35215499A patent/JP3223317B2/ja not_active Expired - Fee Related

Patent Citations (11)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events